The plain language summary of results is a presentation of the findings of a clinical trial, to be submitted in addition to the scientific summary of results, in a format understandable to laypersons. The German version of the regulation does not use consistently uniform terminology; the term used here describes the legally mandated summary. It serves participants and the general public, not scientific exchange among experts. <\/p>\n
According to Article 37, Paragraph 4, the summary of results must be written in a manner understandable to laypersons; its content follows Annex V. It includes, among other things, the trial identifier, name and contact of the sponsor, general information on the location, time, objectives, and reasons for the trial, details on the study population, the investigational medicinal products used, adverse effects and their frequency, overall results, comments on the outcome, possible follow-up studies, and references to further information. It must be complete, factual, and free of promotional exaggeration. <\/p>\n
The summary of results must be submitted to the EU database within one year after the end of the trial. For pediatric trials, a six-month deadline applies. If submission is not possible within one year due to scientific reasons detailed in the trial protocol, results must be submitted as soon as they are available; the trial protocol must then include the timing and justification. Language, structure, and examples must be chosen so that individuals without medical training can understand them. <\/p>\n
Good comprehensibility requires more than just replacing individual technical terms. The text must explain objectives, procedures, results, uncertainties, and side effects in a coherent sequence. Numbers and illustrations should be clearly integrated; positive and negative results must be presented in a balanced manner. The EU guideline recommends early involvement of laypersons in planning and review to ensure that language, readability, and information needs truly meet the target audience. <\/p>\n
Deadlines and content are often jeopardized by distributed responsibilities after the trial ends. An early designated responsible person, a defined data status, and an approval matrix help to create the lay summary consistently with the scientific summary of results and other CTIS documents, without losing comprehensibility in the final step. <\/p>\n
The clinical study report is a comprehensive technical document with methodological and analytical details. The plain language summary of results is not an abridged study report, but an independent presentation focused on comprehensibility, as per Annex V. Both may be based on the same results but serve different purposes and address different audiences. <\/p>\n
Publication in CTIS is the dissemination channel within the EU database, not the designation for the document itself. In addition to the plain language summary, other information and results documents are published or made accessible there. The sponsor’s task is therefore both timely submission and the comprehensible and complete design of the specific document. <\/p>\n
The quality of the lay summary is measured by the target audience’s understanding, not by the completeness of technical terminology. Before approval, it should therefore be checked whether the study’s objective, procedure, main findings, and limitations are comprehensible without prior knowledge. Short sentences, defined terms, understandable figures, and a balanced presentation of benefits and risks facilitate this. The presentation must neither highlight positive results for marketing reasons nor conceal negative or ambiguous findings. If multiple countries were involved, translations must preserve the meaning, comprehensibility, and local language needs. A review by patients or other laypersons can reveal misunderstandings that an internal expert review might miss. The documented approval process later demonstrates that the summary was not only uploaded on time but was also responsibly created as an independent transparency information. <\/p>\n
A consistent approval process also facilitates later updates and inquiries. Sources, data status, translations, and expert reviews should therefore be versioned. This ensures traceability of the basis on which the public was informed and how comprehensibility was ensured in all affected languages. <\/p>\n
The related terms clinical study report and medical writing concern expert results documentation and its creation, respectively. The plain language summary of results uses these foundations but must be written as an independent transparency document for non-experts. <\/p>\n
Preparation should not begin only after database lock. Medical writing, statistics, pharmacovigilance, data protection, and patient advocacy groups require coordinated sources, clear approval pathways, and sufficient time for comprehensibility review and translation. Errors often arise from raw texts in technical language, unclear presentation of results, or inconsistencies with the scientific summary. A documented review protects against misleading or one-sided statements. <\/p>\n
Full-service CROs like Mediconomics provide support with results planning, medical writing, lay-friendly editing, and coordination with data management and pharmacovigilance. They organize comprehensibility reviews, translation management, quality controls, and the timely provision of documents for CTIS. <\/p>\n
For whom is the plain language summary of results written?<\/strong><\/p>\n It is aimed at individuals without scientific training, particularly participants and the general public.<\/p>\n When is the summary to be submitted?<\/strong><\/p>\n Generally within one year after the end of the trial; for pediatric trials, within six months.<\/p>\n Does it replace the clinical study report?<\/strong><\/p>\n No. The clinical study report and the plain language summary of results serve different purposes and have different levels of detail. <\/p>\n The plain language summary of results is a presentation of the findings of a clinical trial, to be submitted in addition to the scientific summary of results, in a format understandable to laypersons. The German version of the regulation does not use consistently uniform terminology; the term used here describes the legally mandated summary. It […]<\/p>\n","protected":false},"author":10,"featured_media":0,"parent":0,"template":"","meta":{"_acf_changed":false,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"glossary-cat":[21],"class_list":["post-7802","glossary","type-glossary","status-publish","hentry","glossary-cat-clinical-operations-gcp"],"acf":[],"related_terms":"","external_url":"","internal_reference_id":"","_links":{"self":[{"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/glossary\/7802","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/glossary"}],"about":[{"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/types\/glossary"}],"author":[{"embeddable":true,"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/users\/10"}],"version-history":[{"count":0,"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/glossary\/7802\/revisions"}],"wp:attachment":[{"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/media?parent=7802"}],"wp:term":[{"taxonomy":"glossary-cat","embeddable":true,"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/glossary-cat?post=7802"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}Regulatory References<\/h2>\n
\n